BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25977337)

  • 1. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
    Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
    Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Necrosis Factor Receptor-1 (p55) Deficiency Attenuates Tumor Growth and Intratumoral Angiogenesis and Stimulates CD8
    Rodriguez YI; Campos LE; Castro MG; Bannoud N; Blidner AG; Filippa VP; Croci DO; Rabinovich GA; Alvarez SE
    Cells; 2020 Nov; 9(11):. PubMed ID: 33202705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
    Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
    Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trophoblastic cell lines generated from tumour necrosis factor receptor-deficient mice reveal specific functions for the two tumour necrosis factor receptors.
    Rasmussen CA; Pace JL; Banerjee S; Phillips TA; Hunt JS
    Placenta; 1999; 20(2-3):213-22. PubMed ID: 10195744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.
    Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ
    J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice.
    Tabbekh M; Franciszkiewicz K; Haouas H; Lécluse Y; Benihoud K; Raman C; Mami-Chouaib F
    J Immunol; 2011 Jul; 187(1):102-9. PubMed ID: 21622855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-1 cells promote immunosurveillance against murine melanoma in host absence of CCR5: new perspective in autologous vaccination therapy.
    Vivanco BC; Viana JD; Perez EC; Konno FT; Guereschi MG; Xander P; Keller AC; Lopes JD
    Immunobiology; 2014 Nov; 219(11):845-9. PubMed ID: 25104402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8
    Kobayashi T; Oishi K; Okamura A; Maeda S; Komuro A; Hamaguchi Y; Fujimoto M; Takehara K; Matsushita T
    J Invest Dermatol; 2019 Jul; 139(7):1535-1544.e1. PubMed ID: 30836062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation.
    Kimura T; Sugaya M; Oka T; Blauvelt A; Okochi H; Sato S
    Oncotarget; 2015 Jul; 6(20):18081-93. PubMed ID: 26098776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice.
    Soudja SM; Wehbe M; Mas A; Chasson L; de Tenbossche CP; Huijbers I; Van den Eynde B; Schmitt-Verhulst AM
    Cancer Res; 2010 May; 70(9):3515-25. PubMed ID: 20406967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.
    Sektioglu IM; Carretero R; Bulbuc N; Bald T; Tüting T; Rudensky AY; Hämmerling GJ
    Cancer Res; 2017 Jan; 77(2):291-302. PubMed ID: 27879269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.